ImmunoGen, Inc. (IMGN): Price and Financial Metrics

ImmunoGen, Inc. (IMGN): $15.52

0.81 (+5.51%)

POWR Rating

Component Grades








Add IMGN to Watchlist
Sign Up

Industry: Biotech




#141 of 382

in industry

IMGN Price/Volume Stats

Current price $15.52 52-week high $15.60
Prev. close $14.71 52-week low $3.10
Day low $14.66 Volume 2,061,607
Day high $15.60 Avg. volume 5,403,194
50-day MA $9.25 Dividend yield N/A
200-day MA $6.03 Market Cap 3.51B

IMGN Stock Price Chart Interactive Chart >


  • IMGN scores best on the Sentiment dimension, with a Sentiment rank ahead of 73.44% of US stocks.
  • The strongest trend for IMGN is in Sentiment, which has been heading up over the past 179 days.
  • IMGN ranks lowest in Stability; there it ranks in the 3rd percentile.

IMGN Stock Summary

  • The ratio of debt to operating expenses for IMMUNOGEN INC is higher than it is for about merely 9.27% of US stocks.
  • IMGN's price/sales ratio is 25.63; that's higher than the P/S ratio of 94.94% of US stocks.
  • The volatility of IMMUNOGEN INC's share price is greater than that of 92.33% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to IMMUNOGEN INC are BGRY, ABEO, SRZN, ONTX, and MRNS.
  • Visit IMGN's SEC page to see the company's official filings. To visit the company's web site, go to

IMGN Valuation Summary

  • IMGN's price/sales ratio is 26.2; this is 413.73% higher than that of the median Healthcare stock.
  • Over the past 243 months, IMGN's price/sales ratio has gone up 6.1.

Below are key valuation metrics over time for IMGN.

Stock Date P/S P/B P/E EV/EBIT
IMGN 2023-05-23 26.2 25.9 -13.2 -12.5
IMGN 2023-05-22 27.2 26.9 -13.7 -13.0
IMGN 2023-05-19 26.7 26.4 -13.4 -12.7
IMGN 2023-05-18 25.7 25.5 -12.9 -12.2
IMGN 2023-05-17 26.1 25.8 -13.1 -12.4
IMGN 2023-05-16 25.7 25.4 -12.9 -12.2

IMGN Growth Metrics

    The 4 year cash and equivalents growth rate now stands at 95.39%.
  • Its 5 year net income to common stockholders growth rate is now at 37.06%.
  • The year over year cash and equivalents growth rate now stands at 54.58%.
IMGN's revenue has moved up $13,336,000 over the prior 33 months.

The table below shows IMGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 95.607 -215.477 -201.093
2022-06-30 89.442 -186.309 -160.677
2022-03-31 92.228 -166.197 -129.397
2021-12-31 69.856 -169.416 -139.303
2021-09-30 127.662 -115.007 -70.743
2021-06-30 136.641 -110.612 -55.778

IMGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IMGN has a Quality Grade of C, ranking ahead of 34.67% of graded US stocks.
  • IMGN's asset turnover comes in at 0.393 -- ranking 121st of 682 Pharmaceutical Products stocks.
  • TARO, HTBX, and ENTA are the stocks whose asset turnover ratios are most correlated with IMGN.

The table below shows IMGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.393 1 1.722
2021-06-30 0.437 1 1.612
2021-03-31 0.442 1 1.694
2020-12-31 0.452 1 2.339
2020-09-30 0.347 1 9.437
2020-06-30 0.327 1 10.967

IMGN Price Target

For more insight on analysts targets of IMGN, see our IMGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.79 Average Broker Recommendation 1.55 (Moderate Buy)

ImmunoGen, Inc. (IMGN) Company Bio

Immunogen develops targeted anticancer therapeutics. The Company's ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The company was founded in 1981 and is based in Waltham, Massachusetts.

IMGN Latest News Stream

Event/Time News Detail
Loading, please wait...

IMGN Latest Social Stream

Loading social stream, please wait...

View Full IMGN Social Stream

Latest IMGN News From Around the Web

Below are the latest news stories about IMMUNOGEN INC that investors may wish to consider to help them evaluate IMGN as an investment opportunity.

Dr. Reddy's (RDY) Meets Goals in Actemra Biosimilar Study

Dr. Reddy's (RDY) announces meeting primary and secondary endpoints in the phase I study of its proposed tocilizumab biosimilar for the treatment of rheumatoid arthritis in adults.

Yahoo | June 6, 2023

An Intrinsic Calculation For ImmunoGen, Inc. (NASDAQ:IMGN) Suggests It's 47% Undervalued

Key Insights The projected fair value for ImmunoGen is US$29.06 based on 2 Stage Free Cash Flow to Equity Current share...

Yahoo | June 6, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the week off right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!

William White on InvestorPlace | June 5, 2023

ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Dips

ImmunoGen and Day One unveiled promising cancer treatment updates over the weekend, leading IMGN stock and DAWN stock to soar Monday.

Yahoo | June 5, 2023

ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer

WALTHAM, Mass., June 04, 2023--ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer

Yahoo | June 4, 2023

Read More 'IMGN' Stories Here

IMGN Price Returns

1-mo 12.87%
3-mo 310.58%
6-mo 201.95%
1-year 285.11%
3-year 223.33%
5-year 55.12%
YTD 212.90%
2022 -33.15%
2021 15.04%
2020 26.35%
2019 6.35%
2018 -25.12%

Continue Researching IMGN

Want to see what other sources are saying about ImmunoGen Inc's financials and stock price? Try the links below:

ImmunoGen Inc (IMGN) Stock Price | Nasdaq
ImmunoGen Inc (IMGN) Stock Quote, History and News - Yahoo Finance
ImmunoGen Inc (IMGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!